Precigen (PGEN) Research & Development (2012 - 2026)
Precigen (PGEN) posted quarterly Research & Development of $5.6 million for Q1 2026, down 46.19% year-over-year from $10.5 million in Q1 2025, and down 19.34% quarter-over-quarter from $7.0 million in Q4 2025.
Precigen (PGEN) Research & Development (2012 - 2026) Analysis & Trends
Precigen (PGEN) has reported Research & Development for 15 consecutive years, with $5.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development fell 46.19% year-over-year to $5.6 million; the TTM figure through Mar 2026 stood at $36.5 million (down 25.98% YoY), while the FY2025 annual figure was $41.3 million, down 22.12% from the prior year.
- Research & Development slipped to $5.6 million in Q1 2026 per PGEN's latest filing, from $7.0 million in the prior quarter.
- Across five years, Research & Development topped out at $15.7 million in Q2 2024 and bottomed at $5.6 million in Q1 2026.
- Historically, Research & Development has averaged $11.5 million across 5 years, with a median of $11.8 million in 2022.
- Annual changes were most pronounced in 2024 — Research & Development surged 32.16% — and 2026, when it plunged 46.19%.
- Precigen's Research & Development stood at $10.8 million in 2022, then gained by 20.39% to $13.0 million in 2023, then retreated by 9.51% to $11.8 million in 2024, then plunged by 40.55% to $7.0 million in 2025, then dropped by 19.34% to $5.6 million in 2026.
- Business Quant data shows PGEN's Research & Development at $5.6 million in Q1 2026, $7.0 million in Q4 2025, and $12.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Precigen | 2.18 Bn | 2.18 Bn | 52.17 Mn | 7.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.28 Mn |
| Mar 31, 2026 | 5.64 Mn |
| Dec 31, 2025 | 6.99 Mn |
| Sep 30, 2025 | 12.38 Mn |
| Jun 30, 2025 | 11.49 Mn |
| Mar 31, 2025 | 10.48 Mn |
| Dec 31, 2024 | 11.76 Mn |
| Sep 30, 2024 | 11.37 Mn |
| Jun 30, 2024 | 15.69 Mn |
| Mar 31, 2024 | 14.25 Mn |
| Dec 31, 2023 | 12.99 Mn |
| Sep 30, 2023 | 11.58 Mn |
| Jun 30, 2023 | 11.87 Mn |
| Mar 31, 2023 | 12.16 Mn |
| Dec 31, 2022 | 10.79 Mn |
| Sep 30, 2022 | 12.62 Mn |
| Jun 30, 2022 | 11.95 Mn |
| Mar 31, 2022 | 11.80 Mn |
| Dec 31, 2021 | 12.18 Mn |
| Sep 30, 2021 | 12.43 Mn |